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irreversible [4, 11] . In the era of enzyme replacement therapy, sensitive assess ment and monitoring of skeletal disease are critical to timely intervention before perma nent dis ability is incurred [4] . Quantitative MRI based methods have been developed to measure bone marrow infiltration in GD. The most promising is Dixon quantitative chemical shift imaging (QCSI) [12] . Results of QCSI of the lumbar spine are reproducible [13] , correlate with disease activity as in dicated by spleen size [14] , and are sensitive for bone marrow response to enzyme replace ment therapy [9] . Despite these advan tages, QCSI is available at only a few academic centers worldwide and thus is not a realistic option in most clinical settings.
Because of the practical limitations of QCSI, multiple semiquantitative approaches to bone marrow disease in GD have been developed, including a variety of scoring systems based on predictable changes in MR signal intensity and anatomic distribution [15] . The characteristic progression of disease within the femur, from proximal metaphysis to diaphysis to proximal and then distal epi physis, has been the principal, if not the sole, criterion on which most previously reported scoring systems have been based. Reflecting this bias, in current published imaging guide lines [4] and actual clinical practice, MRI evaluation of skeletal disease in GD is often limited to the femurs. Maas and colleagues [16] proposed an alternative bone marrow burden scoring system that in corpo rates signal intensity and distribution para meters for the lumbar spine in addition to the femurs. In an investigation in which the subjects were 30 patients with previously untreated GD, Maas et al. found promising features of the bone marrow burden in terms of reproduc ibility, correlation with QCSI findings, and sensitivity as an indicator of response to enzyme replacement therapy.
In this study, we sought to apply the bone marrow burden scoring system to a large, unselected group of patients with GD and to explore correlations between bone marrow burden score and genotype and additional clinical parameters, such as liver volume, spleen status, age, cumulative duration of enzyme replacement therapy, and cumulative duration of untreated disease.
Materials and Methods Subjects
The study was approved by the institutional human investigation committee, which waived the requirement for informed consent, and was com pliant with the HIPAA. The study was performed at a university hospital that is a regional referral center for GD. A computer search of the institu tional imaging report database was per formed to identify patients with GD who under went MRI of the lumbar spine and femurs between January 2002 and March 2006. All available corre sponding medical records were reviewed for clinical parameters of interest. Patients were retrospectively included in the study if simul taneous sagittal T1weighted and STIR images (or, in the case of two patients, fatsuppressed T2 weighted images) of the lumbar spine and coronal T1weighted and STIR images of the femurs were available; liver and spleen volumes had been calculated on the basis of findings on concurrent volumetric MRI of the abdomen; genotype analysis had been performed; and a history of enzyme replacement therapy was available, including the date of initiation and the chronology of regimen changes. Patients younger than 18 years were ex cluded from the study to minimize the confound ing effect of hematopoietic bone marrow. In this review, 47 patients with GD were identified and formed the study population.
Imaging Protocol
All patients underwent MRI of the lumbar spine and both femurs with a 1.5T system. Lumbar spinal imaging was performed with a phased array spine coil and consisted of a sagittal T1 weighted sequence (TR/TE, 600/13; bandwidth, 15 
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Results
The clinical information and imaging data are summarized in Table 3 . The study popu lation consisted of 47 patients (27 women, 20 men; mean age, 44.6 years; range, 18-71 years). All patients had at least one copy of the N370S allele. Nineteen (40%) of the patients were homozygous for N370S, and 28 (60%) were compound heterozygous with one N370S allele and one other mutant allele. Genotypes in the heterozygous group were distributed as follows: eight patients (17% of total study population) with N370S/L444P, seven (15%) with N370S/84GG, six (13%) with N370S/IVS+2, five (11%) with N370S/? (the question mark denoting an un charac terized mutant allele), and one (2%) each with N370S/R131L and N370S/V394L. 
Bone Marrow Burden Evaluation
Two radiologists with 10 and 3 years of experience analyzed all MR images and assigned bone marrow burden scores by consensus. Both readers were blinded to clinical parameters. Bone marrow burden scores at each anatomic location were based on signal intensity and distribution according to a modified version of previously published criteria [16] (Tables 1 and 2 ) and ranged from 0 to 8 for the lumbar spine (Figs. 1-4) and from 0 to 8 for the femurs (Figs. 5-7), for an overall score of 0-16. For determining the fem oral site of involvement, hip or knee replace ment was inter preted as evidence of proximal or distal femoral epiphyseal disease. In all equivocal cases, scoring was performed according to a worstcase standard.
Clinical Data
Clinical data acquisition was conducted by one author and included patient age and sex, genotype, liver and spleen volumes (calculated from con current findings on volumetric MRI of the abdomen), history of splenectomy, and details of enzyme replacement therapy (date of initiation and chronology of regimen changes). Because all patients had at least one copy of the N370S allele, for primary data analysis, genotype was classified as N370S homozygous and N370S compound heterozygous. Because nearly one half (20 of 47) of the patients had undergone splenectomy, spleen status was treated as a categoric variable, with a value of 0 for spleen size within the range of normal, 1 for an enlarged spleen (> 200 cm 2 in diameter), and 2 for a surgically absent spleen. Regarding the statistical analysis of enzyme replacement therapy, both the cumulative duration of therapy and the cumulative duration of un treated disease (defined as age minus cumulative duration of enzyme re placement therapy) were considered.
Statistical Analysis
Data were analyzed with SAS software (version 9.1, SAS). Differences between groups were analyzed with the nonparametric Wilcoxon's test. Correlation was calculated with twotailed non parametric Spearman's rank correlation (ρ). A value of p < 0.05 was considered significant. untreated disease. The homozygous and compound heterozygous groups did not differ significantly in age distribution, cumulative duration of enzyme replacement therapy, or cumulative duration of untreated disease. There were, however, significantly more women in the homozygous group (79%, 15 of 19) than in the heterozygous group (43%, 12 of 28) (p = 0.02). 
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Compound heterozygotes had more severe skeletal disease than did homozygotes, having higher overall bone marrow burden scores (p < 0.001), lumbar spinal bone marrow burden scores (p < 0.01), and femoral bone marrow burden scores (p < 0.01) ( Table 4 , Fig. 8 ).
Within the homozygous group, overall bone marrow burden scores ranged from 0 to 15 (median, 6), lumbar spinal bone marrow burden scores from 0 to 8 (median, 3), and femoral bone marrow burden scores from 0 to 8 (median, 3). Within the heterozygous group, L444P and one each with N370S/84GG, N370S/?, and N370S/R131L. Perhaps owing to the small numbers of patients, there were no statistically significant differences in skeletal disease between the various compound heterozygous subgroups. Femur and lumbar spine bone marrow burden scores were weakly but significantly correlated across all patients (ρ = 0.40, p < 0.01) (Fig. 9) . In subgroup analysis, this correlation persisted for the compound heterozygotes (ρ = 0.43, p = 0.02) but was nonexistent among the N370S homozygotes (ρ = -0.04, p = 0.87). The difference, however, was not statistically significant (p = 0.12).
Considering all patients, there was a significant association between an enlarged or surgically absent spleen and more severe bone marrow infiltration in both the axial and appendicular skeletons, reflected as positive correlations between spleen status and overall bone marrow burden score (ρ = 0.51, p < 0.001), lumbar spinal bone marrow burden score (ρ = 0.43, p < 0.01), and femoral bone marrow burden score (ρ = 0.42, p < 0.01) ( Table 4) . In subgroup analysis, there was a trend toward greater skeletal disease with abnormal spleen status in all instances except for femoral bone marrow burden in the N370S homozygous group. This trend, however, was significant only for overall bone marrow burden score (ρ = 0.46, p = 0.01) and femoral bone marrow burden score (ρ = 0.47, p = 0.01) in the compound heterozygous group.
There was a significant negative correlation between liver volume and cumulative duration of enzyme replacement therapy across all patients (ρ = -0.42, p < 0.01). This trend was also found in subgroup analysis and was significant for homozygotes (ρ = -0.56, p = 0.01) but not for compound heterozygotes (ρ = -0.36, p = 0.06). There were no significant associations between skeletal disease and liver volume, age, cumulative duration of enzyme replacement therapy, or cumulative duration of untreated disease.
Discussion
To our knowledge, this study is the first to implement bone marrow burden scoring in an unselected group of patients with GD and to explore the relation between bone marrow burden score and genotype. Our subjects were generally representative of the U.S. population of patients with GD in terms of distribution of genotypes and prevalence of enzyme re placement therapy. The severity of bone mar row infiltration correlated signifi cantly with 
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overall bone marrow burden scores ranged from 2 to 16 (median, 10), lumbar spinal bone marrow burden scores from 0 to 8 (median, 5), and femoral bone marrow burden scores from 2 to 8 (median, 6). Considering all genotypes with at least five patients, N370S/ L444P was associated with the greatest burden of skeletal disease (median overall bone marrow burden score, 11). All five patients with maximal skeletal disease (overall bone marrow burden score, 16) were compound heterozygotes, two with N370S/ genotype, specifically with the number of copies of the N370S allele. Homozygotes with two copies of the N370S allele had significantly lower bone marrow burden scores than compound heterozygotes with only one copy of the N370S allele.
Although there were no statistically significant differences between the compound heterozygote subgroups, the N370S/L444P genotype was associated with uniformly severe skeletal disease, two of eight patients having the maximum possible bone marrow burden score and five of eight patients having advanced irreversible pathologic changes in the form of having undergone total joint replacement or having vertebral compression fractures. Severe bone marrow burden was also generally evident in the N370S/IVS+2 and N370S/? genotypes. The N370S/84GG genotype exhibited substantial variability in degree of bone marrow infiltration.
The correlation between genotype and bone marrow burden in our study was gen erally concordant with published data re garding associations between genotype and disease severity in GD. The ameliorative effect of the N370S allele and the unfavorable effect of other mutations, particularly L444P, are well known and appear partially at trib utable to differential gluco cerebrosidase en zyme activity. For example, PasmanikChor and colleagues [17] , using a vaccinia virusderived system to express normal and mu tated glucocerebrosidase in human cells, found that the N370S enzyme has activity com parable with that of its normal counterpart, Tables 1 and 2 for scanning criteria.
The relation between spleen status and bone marrow burden in our study was in agreement with earlier observations. Patients who had undergone splenectomy or who had splenomegaly had significantly higher bone marrow burden scores, both in the axial and negative finding but must be interpreted with caution given that our primary objective was to explore the association between genotype and skeletal disease. Enzyme replacement therapy was at best a secondary consideration, incorporated mainly to mitigate its potential as a confounding factor. This investigational bias is reflected in our method, particularly its static framework, which handicapped our ability to discern the influence of enzyme replacement therapy on bone marrow disease over time. Numerous previous studies have shown that enzyme replacement therapy de creases glucocerebroside accumulation and increases normal fat content in bone marrow [11] . In the earlier studies, longitudinal data were used to explore intraindividual rather than interindividual differences related to enzyme replacement therapy. Future investi gations incorporating longitudinal bone mar row burden data are needed, not only to validate the sensitivity of bone marrow burden scoring as an indicator of response to enzyme replacement therapy but also to assess the relation between genotype and the efficacy of enzyme replacement therapy.
Femoral and lumbar spinal bone marrow burden scores correlated only weakly, but each score independently illustrated both the pro tective role of the N370S allele and the unfavorable implication of splenectomy. These results suggest the phenotypic complexity of GD applies not only to individual organ systems but also to the axial and appendicular compartments of the skeleton. If, as Maas and colleagues [16] propose, lumbar bone marrow burden is more reflective of reversible patho logic changes but femoral bone marrow burden is more indicative of static disease, it is natural that these two parameters would overlap to some extent while still conveying distinct information. The multiplecompart ment ap proach of bone marrow burden is an advance over previous scoring systems and highlights the limitation of imaging protocols restricted to the femurs.
In implementing bone marrow burden scor ing, we encountered a few practical chal lenges that were fairly easily overcome. The Maas bone marrow burden guidelines are based on nonfatsuppressed fast spinecho T2weighted sequences instead of STIR sequences. STIR imaging is compatible with the premise of bone marrow burden scoring because the inversion pulse affects fat signal intensity uniformly regardless of location. However, with STIR imaging, the femoral signal intensity categories slightly hypo intense and hypointense relative to sub cutan eous fat are no longer applicable, necessitat ing a modified bone marrow burden scoring system that omits these designations. Because our methods deviated from those in the original report by Maas and colleagues [16] , neither the reproducibility nor the validity of our bone marrow burden scores can be assumed. Despite this limitation, we believe STIR imaging is justified because of its appendicular skeletons, than did those with intact, normalsized spleens. This finding sub stantiates a previously reported [18] asso ciation between splenectomy and skele tal le sions and supports the notion that com promise of the splenic reservoir of GD cells accelerates progression of disease in other compartments. The absence of a significant correlation be tween enzyme replacement therapy and bone marrow infiltration is our most striking deMayo et al.
superior sensitivity for bone marrow edema compared with a longTE sequence without fat suppression.
The bone marrow burden criteria were developed and validated for previously untreated patients with GD, presumably with less advanced disease and a low prevalence, if any, of joint replacement. In our study group, 10 of 47 patients had a total of 12 hip and three knee prostheses, which we inter preted as evidence of proximal or distal femoral epiphyseal involvement. Certain clinical scenarios in GD occur with sufficient frequency that they must be anticipated and explicitly addressed in an optimal scoring system. We believe joint prostheses fall into this category.
Bone marrow burden scoring is ideally suited to ranking disease as it progresses along a predictable continuum of anatomic distribution or signal intensity, but the patho logic process frequently deviates from its expected trajectory or fails to fit neatly into a single category. One patient in our study, for example, had infarction of the distal but not the proximal femoral epiphyses. We assigned her femoral site of involvement three points, deliberately overlooking the fact that her disease skipped a location (Fig. 10) . Because these types of inconsistencies are inevitable in any categoric scoring system, we support general standards for resolving them, such as the worstcase approach, to minimize subject ivity in interpretation.
The bone marrow burden system does not explicitly address irreversible pathologic ske letal changes such as infarction, osteo necrosis, and fracture, a bias justified by its designers on the grounds that "irreversible components would be relatively insensitive to subtle changes in bone marrow invasion" [16] . Consequently, at times the bone marrow burden indicates the presence of discrete, likely irreversible complications in the cur rency of continuous, reversible bone marrow infiltration, giving the false impression the two processes are, with appropriate weight ing, equivalent. This approach is exemplified by the symmetry of the point system used for T2 relaxation, in which equal values are assigned to hypointense bone marrow in filtrated by GD cells and to hyperintense bone marrow that may be infarcted. Chronic irreversible change can inflate the bone marrow burden and exaggerate the im pression of reversible bone marrow in filtration, as illustrated by the four patients in our study with a femoral score of 6 or 7 but a lumbar spinal score of 0. All of these patients had evidence of chronic medullary infarcts in the femurs (in three cases confirmed after review of longitudinal MRI data not considered during bone marrow burden assessment) but no signs of reversible bone marrow disease.
Limitations of our study included its retro spective design, relatively small numbers of patients in each subgroup (which may account for the lack of a clear statistical relation between bone marrow burden scores and specific compound heterozygous sub groups), lack of verification of results against the reference standard of Dixon QCSI, and absence of longitudinal data for assessment of changes in bone marrow burden related to natural progression of disease or response to enzyme replacement therapy.
The semiquantitative MRIbased bone marrow burden score indicates the presence of marked ameliorative and adverse effects of the N370S allele and splenectomy, re spectively, on bone marrow disease in GD. Axial and appendicular bone marrow burden scores convey related but distinct information and should be individually evaluated. The bone marrow burden scoring system rep resents an advance in terms of multiple compartment evaluation of skeletal disease in GD but is limited by lack of differentiation of reversible and irreversible pathologic changes. Future investigation is needed to address this limitation and to explore the interplay between axial and appendicular forms of disease and between genotype and the efficacy of enzyme replacement therapy. 
